Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension.
Cardiomyopathy
heart failure
pulmonary hypertension
pulmonary vascular remodeling
restrictive mitral annuloplasty (RMA)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
This study retrospectively examined the association between elevated trans-pulmonary gradient (TPG), which reflects pre-capillary contribution to pulmonary hypertension (PH), and postoperative pulmonary hemodynamics and outcomes following restrictive mitral annuloplasty (RMA) in patients with pre-existing PH. Pre- and postoperative (1 month) cardiac catheterization was performed in 64 patients with severely impaired left ventricular function (i.e., ejection fraction ≤40%) and pre-existing PH (mean pulmonary artery pressure (PAP) ≥25 mmHg) who underwent RMA. Patients were segregated into two groups: low TPG (≤12 mmHg) and elevated TPG (>12 mmHg). The mean follow-up period was 54±27 months. The primary outcome seen was a change in pulmonary hemodynamics after RMA; secondary outcomes were composite adverse events, including all-cause mortality and readmission for heart failure. Compared to the low TPG group, patients in the elevated TPG group were more likely to show a postoperative mean PAP of ≥25 mmHg (84% Elevated TPG negatively affects postoperative pulmonary hemodynamics and late outcomes in patients with advanced cardiomyopathy and pre-existing PH who have undergone RMA. These findings suggest that the assessment of TPG should be included in post-RMA risk stratification.
Sections du résumé
BACKGROUND
BACKGROUND
This study retrospectively examined the association between elevated trans-pulmonary gradient (TPG), which reflects pre-capillary contribution to pulmonary hypertension (PH), and postoperative pulmonary hemodynamics and outcomes following restrictive mitral annuloplasty (RMA) in patients with pre-existing PH.
METHODS
METHODS
Pre- and postoperative (1 month) cardiac catheterization was performed in 64 patients with severely impaired left ventricular function (i.e., ejection fraction ≤40%) and pre-existing PH (mean pulmonary artery pressure (PAP) ≥25 mmHg) who underwent RMA. Patients were segregated into two groups: low TPG (≤12 mmHg) and elevated TPG (>12 mmHg). The mean follow-up period was 54±27 months. The primary outcome seen was a change in pulmonary hemodynamics after RMA; secondary outcomes were composite adverse events, including all-cause mortality and readmission for heart failure.
RESULTS
RESULTS
Compared to the low TPG group, patients in the elevated TPG group were more likely to show a postoperative mean PAP of ≥25 mmHg (84%
CONCLUSIONS
CONCLUSIONS
Elevated TPG negatively affects postoperative pulmonary hemodynamics and late outcomes in patients with advanced cardiomyopathy and pre-existing PH who have undergone RMA. These findings suggest that the assessment of TPG should be included in post-RMA risk stratification.
Identifiants
pubmed: 34164167
doi: 10.21037/jtd-20-2898
pii: jtd-13-05-2746
pmc: PMC8182535
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2746-2757Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-2898). The authors have no conflicts of interest to declare.
Références
J Thorac Cardiovasc Surg. 2011 Oct;142(4):783-92
pubmed: 21397266
Nat Rev Cardiol. 2010 Nov;7(11):648-59
pubmed: 20924360
J Am Coll Cardiol. 1992 Jan;19(1):48-54
pubmed: 1729345
JACC Heart Fail. 2014 Jun;2(3):230-7
pubmed: 24952689
Eur Heart J. 2007 Mar;28(5):569-74
pubmed: 17314112
J Am Coll Cardiol. 2008 Jul 29;52(5):319-26
pubmed: 18652937
Circ J. 2011;75(3):571-9
pubmed: 21187659
J Heart Lung Transplant. 2010 Nov;29(11):1253-8
pubmed: 20620083
J Heart Lung Transplant. 2007 Apr;26(4):312-8
pubmed: 17403470
J Heart Transplant. 1990 Sep-Oct;9(5):526-37
pubmed: 2231091
J Cardiol. 2015 Oct;66(4):279-85
pubmed: 25851471
Ann Intern Med. 1992 Jun 1;116(11):888-95
pubmed: 1580444
J Thorac Cardiovasc Surg. 2018 Aug;156(2):630-638.e1
pubmed: 29395191
Eur Heart J. 2009 Oct;30(20):2493-537
pubmed: 19713419
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54
pubmed: 19555858
Am J Cardiol. 2003 Mar 1;91(5):538-43
pubmed: 12615256
ESC Heart Fail. 2020 Aug;7(4):1560-1570
pubmed: 32400096
Am Heart J. 1993 Oct;126(4):896-904
pubmed: 8213447
Circulation. 2011 Sep 13;124(11 Suppl):S97-106
pubmed: 21911824
Eur Heart J. 2016 Mar 21;37(12):942-54
pubmed: 26508169
Am J Cardiol. 2011 Mar 1;107(5):755-60
pubmed: 21316508